SCHEMBL5478136

SCHEMBL5478136

CC(C)(C)c1ccc(Nc2cc(NCc3ccccn3)ncn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.49
ABCB1 P08183 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
TRPV1 Q8NER1 2/20 0.47
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAOA P21397 3/20 0.44
MAOB P27338 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5474449 0.84 JAK3 (0.51) NPC1RAB9AKDM4EALDH1A1NPSR1
SCHEMBL12749699 0.81 MAOA (0.67) NPC1RAB9AKDM4EALDH1A1NPSR1
SCHEMBL5477078 0.80 ABL1 (0.48) ABCB1ABCG2TRPV1ALDH1A1NPSR1
SCHEMBL5477065 0.80 MAP4K4 (0.42) NPC1RAB9ATRPV1ALDH1A1CYP1A2
SCHEMBL5477172 0.80 MAPK1 (0.45) NPC1RAB9ATRPV1KDM4EALDH1A1
SCHEMBL5475280 0.79 CYP1A2 (0.53) ABCB1ABCG2NPC1KDM4EALDH1A1
SCHEMBL5476185 0.78 CYP1A2 (0.58) NPC1RAB9AKDM4EALDH1A1CYP1A2
SCHEMBL5466964 0.78 CYP2C19 (0.48) NPC1RAB9ATRPV1KDM4ECYP1A2
SCHEMBL18466142 0.78 NPC1 (0.51) KCNH2NPC1RAB9AKDM4EALDH1A1
SCHEMBL5483168 0.77 POLB (0.48) KDM4ECYP1A2MAPTCYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161637-A1 Substituted pyridin-2-ylamine analogues NEUROGEN CORPORATION (US) 2007-07-12 US claimed
EP-1648877-A1 SUBSTITUTED PYRIDIN-2-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-04-26 EP claimed
WO-2005009980-A1 SUBSTITUTED PYRIDIN-2-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2005-02-03 WO claimed
US-20070161637-A1 Substituted pyridin-2-ylamine analogues NEUROGEN CORPORATION (US) 2007-07-12 US disclosed
US-20070161637-A1 Substituted pyridin-2-ylamine analogues NEUROGEN CORPORATION (US) 2007-07-12 US disclosed
US-20070161637-A1 Substituted pyridin-2-ylamine analogues NEUROGEN CORPORATION (US) 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161637-A1 Substituted pyridin-2-ylamine analogues PIGS, GPR35, GPR174 KCNH2 2217/4885ABCB1 2090/4885ABCG2 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.